KR20090061727A - 인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 - Google Patents
인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 Download PDFInfo
- Publication number
- KR20090061727A KR20090061727A KR1020070128640A KR20070128640A KR20090061727A KR 20090061727 A KR20090061727 A KR 20090061727A KR 1020070128640 A KR1020070128640 A KR 1020070128640A KR 20070128640 A KR20070128640 A KR 20070128640A KR 20090061727 A KR20090061727 A KR 20090061727A
- Authority
- KR
- South Korea
- Prior art keywords
- ctrp1
- human
- sirna
- seq
- cardiovascular disease
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
Abstract
Description
Claims (16)
- 인간 CTRP1의 생성을 억제하는 인간 CTRP1 유전자의 siRNA.
- 제1항에 있어서, 서열 번호 3과 서열 번호 4의 폴리뉴클레오티드 쌍을 갖는, 인간 CTRP1 유전자의 siRNA.
- 제1항에 있어서, 서열 번호 5와 서열 번호 6의 폴리뉴클레오티드 쌍을 갖는, 인간 CTRP1 유전자의 siRNA.
- 인간 CTRP1의 생성을 억제하거나 인간 CTRP1의 기능을 억제하는 물질을 포함하는 고혈압 또는 심혈관질환 치료용 약학조성물.
- 제4항에 있어서, 인간 CTRP1의 생성을 억제하는 물질로서 인간 CTRP1 유전자의 siRNA를 포함하는 고혈압 또는 심혈관질환 치료용 약학조성물.
- 제5항에 있어서, 인간 CTRP1의 생성 억제 물질로서 서열 번호 3과 서열 번호 4의 폴리뉴클레오티드 쌍을 갖는 siRNA 및 서열 번호 5와 서열 번호 6의 폴리뉴클레오티드 쌍을 갖는 siRNA 중 1종 이상을 포함하는 고혈압 또는 심혈관질환 치료용 약학조성물.
- 제4항에 있어서, 인간 CTRP1의 기능을 억제하는 물질로서 인간 CTRP1의 항체를 포함하는 고혈압 또는 심혈관질환 치료용 약학조성물.
- 제7항에 있어서, 인간 CTRP1의 항체가 하이브리도마 세포주 E21H7에 의해 생산되는 단일클론 항체인 고혈압 또는 심혈관질환 치료용 약학조성물.
- 인간 CTRP1 유전자 또는 인간 CTRP1 단백질을 포함하는, 고혈압 또는 심혈관질환 치료제 스크리닝 조성물.
- 제9항에 있어서, 인간 CTRP1 유전자가 서열 번호 1의 염기 서열, 또는 그 변이체, 및 서열 번호 1 또는 그 변이체의 단편 염기 서열에서 선택된 1종인 것인 고혈압 또는 심혈관질환 치료제 스크리닝 조성물.
- 제9항에 있어서, 인간 CTRP1 단백질이 서열 번호 2의 아미노산 서열을 갖거나, 또는 서열 번호 1의 염기 서열 또는 그 변이체로부터 발현된 단백질이거나, 또는 인간 CTRP1과 동등한 생리학적 활성을 나타내는 인간 CTRP1 폴리펩티드 단편인 것인 고혈압 또는 심혈관질환 치료제 스크리닝 조성물.
- 제10항의 스크리닝 조성물을 시험대상 물질과 접촉시키는 단계, 및상기 스크리닝 조성물과 시험대상 물질 사이의 반응을 확인하여, 시험대상 물질이 스크리닝 조성물에 포함된 인간 CTRP1 유전자의 발현을 억제하거나 증가시키는지 여부를 결정하는 단계를 포함하는, 고혈압 또는 심혈관질환 치료제 스크리닝 방법
- 제11항의 스크리닝 조성물을 시험대상 물질과 접촉시키는 단계, 및상기 스크리닝 조성물과 시험대상 물질 사이의 반응을 확인하여, 시험대상 물질이 스크리닝 조성물에 포함된 인간 CTRP1 단백질의 기능을 억제하거나 증가시키는지 여부를 결정하는 단계를 포함하는, 고혈압 또는 심혈관질환 치료제 스크리닝 방법
- 인간 CTRP1 항체를 포함하는 고혈압 또는 심혈관질환 진단 조성물.
- 제14항에 있어서, CTRP1 항체가 하이브리도마 세포주 E21H7에 의해 생산되는 단일클론 항체인 고혈압 또는 심혈관질환 진단 조성물.
- 제14항 또는 제15항의 진단 조성물을 포함하는 고혈압 또는 심혈관질환 진단용 키트.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070128640A KR100976170B1 (ko) | 2007-12-12 | 2007-12-12 | 인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070128640A KR100976170B1 (ko) | 2007-12-12 | 2007-12-12 | 인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090061727A true KR20090061727A (ko) | 2009-06-17 |
KR100976170B1 KR100976170B1 (ko) | 2010-08-16 |
Family
ID=40991071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070128640A KR100976170B1 (ko) | 2007-12-12 | 2007-12-12 | 인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100976170B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101341200B1 (ko) * | 2010-06-22 | 2013-12-12 | 울산대학교 산학협력단 | Trap80 조절제를 유효성분으로 함유하는 대사증후군 치료 또는 예방용 약학조성물 |
KR20150102593A (ko) | 2014-02-28 | 2015-09-07 | 이화여자대학교 산학협력단 | Ctrp1 억제제를 포함하는 미토콘드리아 이상 질환의 치료용 조성물 |
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
WO2019137922A1 (en) * | 2018-01-09 | 2019-07-18 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie | Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation |
-
2007
- 2007-12-12 KR KR1020070128640A patent/KR100976170B1/ko active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101341200B1 (ko) * | 2010-06-22 | 2013-12-12 | 울산대학교 산학협력단 | Trap80 조절제를 유효성분으로 함유하는 대사증후군 치료 또는 예방용 약학조성물 |
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
KR20150102593A (ko) | 2014-02-28 | 2015-09-07 | 이화여자대학교 산학협력단 | Ctrp1 억제제를 포함하는 미토콘드리아 이상 질환의 치료용 조성물 |
WO2019137922A1 (en) * | 2018-01-09 | 2019-07-18 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie | Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation |
Also Published As
Publication number | Publication date |
---|---|
KR100976170B1 (ko) | 2010-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018229487B2 (en) | Treatment of fibrosis | |
Hao et al. | LncRNA-Safe contributes to cardiac fibrosis through Safe-Sfrp2-HuR complex in mouse myocardial infarction | |
Lan et al. | MicroRNA-494 reduces ATF3 expression and promotes AKI | |
Cai et al. | Activated CD4+ T cells-derived exosomal miR-142-3p boosts post-ischemic ventricular remodeling by activating myofibroblast | |
CN108192972B (zh) | 用于乳腺癌转移的诊断、预后和治疗的方法 | |
CA3103154A1 (en) | Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof | |
JP2011256179A (ja) | 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 | |
CA2888122A1 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf | |
AU2014229563A1 (en) | Method for the diagnosis, prognosis and treatment of cancer metastasis | |
KR100976170B1 (ko) | 인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 | |
US8841269B2 (en) | Polynucleotides for use in treating and diagnosing cancers | |
Chen et al. | CircMAPK9 promotes adipogenesis through modulating hsa-miR-1322/FTO axis in obesity | |
Zhang et al. | LGR4: a new receptor member in endocrine and metabolic diseases | |
EP2010673B1 (en) | Means and methods for diagnosing and treating cancer based on the frmd3 gene | |
WO2024003205A1 (en) | Long non-coding rnas as target for treating fibrosis and cancer | |
AU2014236386A1 (en) | TCF7L2 variant and methods of use thereof in diagnostic and drug screening assays | |
JP2006166703A (ja) | 軟骨分化制御遺伝子 | |
KR20100045194A (ko) | Kir2.2 억제제를 포함하는 암 치료용 조성물 | |
KR20100061296A (ko) | 인테그린알파5를 이용한 항암제 또는 sip1/zeb2 저해제의 스크리닝 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130726 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140804 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151106 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161205 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170626 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180625 Year of fee payment: 9 |